The spread of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), firstly detected in Wuhan (China) at the end of 2019, has rapidly reached pandemic status. At the present time, under the “pressure” of the infection the need of effective and innovative treatments is becoming crucial. In particular, new insights into potential innovative therapeutic interventions, including the repositioning of pharmaceutical compounds already available that may be useful to control and contrast coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 are needed, also in the view of potential second waves of infection. With this aim, we here describe the rationale for the use of Idasanutlin, an orally available, potent and selective small-molecule antagonist of MDM2 acting as non-genotoxic p53 activator to treat COVID-19 patients and support its clinical evaluation.

Rationale for Considering Oral Idasanutlin as a Therapeutic Option for COVID-19 Patients

Zauli G.
Primo
;
Tisato V.
Secondo
;
Secchiero P.
Ultimo
2020

Abstract

The spread of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), firstly detected in Wuhan (China) at the end of 2019, has rapidly reached pandemic status. At the present time, under the “pressure” of the infection the need of effective and innovative treatments is becoming crucial. In particular, new insights into potential innovative therapeutic interventions, including the repositioning of pharmaceutical compounds already available that may be useful to control and contrast coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 are needed, also in the view of potential second waves of infection. With this aim, we here describe the rationale for the use of Idasanutlin, an orally available, potent and selective small-molecule antagonist of MDM2 acting as non-genotoxic p53 activator to treat COVID-19 patients and support its clinical evaluation.
2020
Zauli, G.; Tisato, V.; Secchiero, P.
File in questo prodotto:
File Dimensione Formato  
Zauli et al. Front Pharmacol. 2020.pdf

accesso aperto

Descrizione: Full text editoriale
Tipologia: Full text (versione editoriale)
Licenza: Creative commons
Dimensione 379.1 kB
Formato Adobe PDF
379.1 kB Adobe PDF Visualizza/Apri

I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2434953
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 15
social impact